UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced today that it has added to its deep intellectual property portfolio two new U.S. patents related to its proprietary Biclonics® technology for developing novel bispecific antibodies. On September 19, 2017, the United States Patent Office (USPTO) granted U.S. Patent No. 9,765,133, entitled `Antibody Producing Non-Human Mammal`, which marks a first U.S. patent covering a transgenic mouse having a common light chain, related to Merus` MeMo® mouse technology. Using MeMo®, a leading...
|
